Compare OPAD & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAD | AYTU |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 27.4M |
| IPO Year | 2020 | 2015 |
| Metric | OPAD | AYTU |
|---|---|---|
| Price | $2.52 | $2.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $12.25 | $9.67 |
| AVG Volume (30 Days) | ★ 25.0K | 24.7K |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $567,812,000.00 | $27,632,080.00 |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | $56.52 | $27.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.54 | $1.80 |
| 52 Week High | $6.09 | $3.07 |
| Indicator | OPAD | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 36.10 | 41.87 |
| Support Level | $0.63 | $1.94 |
| Resistance Level | $5.51 | $2.34 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 34.18 | 16.58 |
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.